By proceeding, you agree to our Terms of Use and Privacy Policy.
Join us at the 5th Treg Summit, where we will be discussing the latest advancements in IL-2 and CAR-Treg therapies, and how advanced engineering and product design can enhance their tissue specificity, durability, stability, and safety, thus accelerating their clinical translation.With investment in the Treg field at an all-time high, there is an abundance of excitement around the potential for these remarkable cells to revolutionize the treatment of autoimmunity, inflammation, and transplantation. As we witness multiple clinical readouts and several more therapies entering the clinic, it is crucial for Treg trailblazers to come together to assess therapy efficacy, determine safety, and translate the next generation of therapies into the clinic.Returning for its 5th year, the Treg Summit is the premier industry forum for uniting industry and academic experts to advance both cell and non-cell-based approaches, unlocking the potential of Tregs to treat indications with significant unmet clinical needs.Over 3 jam-packed days, we will cover a range of topics, including CAR-, TCR-, and polyclonal Tregs, as well as IL-2, muteins, and small molecules. This unrivaled opportunity to collaborate with peers in the Treg field will allow you to explore clinical advances, discuss challenges, and discover next-gen methods to take Treg therapies to the next level.
Explore clinical advances, discover next-gen methods to take Treg therapies to the next level.
Learn how advanced engineering and product design can enhance tissue specificity, durability, stability, and safety, and accelerate their clinical translation.
Gain unparalleled access to the latest research and industry trends, including CAR-, TCR-, and polyclonal Tregs, as well as IL-2, muteins, and small molecules.
Be at the forefront of the field and part of a community of trailblazers working towards advancing both cell and non-cell-based approaches.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems.
Make faster and better informed drug development decisions In partnership with the world’s leading drug development experts to help you keep up with the pace of preclinical and clinical research developments.
Revolo Biotherapeutics is developing revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases.
For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and
Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology.
PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diab
PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS). PolTREG ha
TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system. TScan Therapeutics was founded in 2018 by a small group of scientists led by Dr. Stephen Elledge (Harvard Medi
TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system. TScan Therapeutics was founded in 2018 by a small group of scientists led by Dr. Stephen Elledge (Harvard Medical School/HHMI). TScan is discovering and develop
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.